Sabirnetug misses primary end point in phase 2 Alzheimer trial; self-guided online program cuts functional seizures in randomized trial

• Research Oct 30, 2026
  Sabirnetug misses 18-month iADRS primary end point in 542-patient phase 2 ALTITUDE-AD trial, and Acumen stops development
  Acumen Pharmaceuticals said Oct. 30 that sabirnetug, an antibody against soluble amyloid beta oligomers, did not meet its primary end point, cognitive and functional decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months, versus placebo at 35 mg/kg or 50 mg/kg in 542 people with early Alzheimer disease. Key secondary end points, including the Clinical Dementia Rating Sum of Boxes, were not significant in the company-reported topline results. Amyloid plaque fell significantly at both doses, and amyloid-related imaging abnormalities with edema occurred in about 10% of treated participants. The company plans to cease development.
  Sources: Acumen Pharmaceuticals, Psychiatric Times
• Research Oct 26, 2026
  Self-guided online program cuts functional seizure frequency versus standard care in 107-patient Australian trial
  In a three-arm randomized trial in JAMA Neurology, adults with functional seizures confirmed by video electroencephalogram received the five-session Re-PROGRAM internet intervention, self-guided or therapist-guided, plus standard care, or standard care alone. In the 96-patient full analysis set, the self-guided arm had fewer monthly seizures than standard care (rate ratio 0.35; 95% CI 0.18 to 0.69; Holm-Bonferroni P = .006), with the effect sustained at 12 months. The therapist-guided arm's seizure reduction was not significant, and the active arms did not differ (rate ratio 0.67; 95% CI 0.33 to 1.36).
  Sources: JAMA Neurology, PubMed

The weekly innovation roundup for neurology, published every Sunday for the week before; every item links to its sources. Latest neurology news · All specialties